Related Experiment Video

Updated: Aug 6, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

[Course of chronic virus hepatitis B in children and attempts at modifying its treatment]

B Kowalik-Mikołajewska1

  • 1Kliniki Chorób Zakaźnych i Pasozytniczych Wieku Dzieciecego Instytutu Chorób Zakaźnych i Pasozytniczych AM, Warszawie.

Polski Tygodnik Lekarski (Warsaw, Poland : 1960)
|March 15, 1993
PubMed

Insights

Isoprinosine showed benefits for children with chronic active hepatitis B, accelerating seroconversion and normalizing aminotransferase levels. Prednisone did not influence the disease course in the studied group.

Area of Science:

  • Hepatology
  • Virology
  • Pediatric Gastroenterology

Context:

  • Chronic Hepatitis B virus infection affects children globally.
  • Long-term management strategies for pediatric chronic hepatitis B are crucial.
  • Assessing antiviral efficacy in pediatric populations requires careful evaluation.

Purpose:

  • To evaluate the efficacy of isoprinosine and prednisone in managing chronic hepatitis B in children.
  • To assess the impact of these treatments on seroconversion and liver enzyme normalization.
  • To compare treatment outcomes with a no-therapy control group.

Summary:

  • A study followed 60 children with chronic hepatitis B, comparing isoprinosine, prednisone, and no therapy.
  • Isoprinosine significantly accelerated HBe antigen seroconversion and aminotransferase normalization in chronic active hepatitis B.
  • Histological recovery was observed in 8 children, with no deaths in any group. Prednisone showed no significant impact.

Impact:

  • Findings suggest isoprinosine as a potentially effective therapeutic option for pediatric chronic active hepatitis B.
  • The study highlights the importance of early intervention and appropriate antiviral therapy.
  • Results contribute to understanding treatment responses in children with chronic viral hepatitis.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...